Characterizing Metastatic HER2 -Positive Gastric Cancer at the CDH1 Haplotype

The gene, coding for the E-cadherin protein, is linked to gastric cancer (GC) susceptibility and tumor invasion. The human epidermal growth factor receptor 2 ( ) is amplified and overexpressed in a portion of GC. is an established therapeutic target in metastatic GC (mGC). Trastuzumab, in combinatio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of molecular sciences 2017-12, Vol.19 (1), p.47
Hauptverfasser: Caggiari, Laura, Miolo, Gianmaria, Buonadonna, Angela, Basile, Debora, Santeufemia, Davide A, Cossu, Antonio, Palmieri, Giuseppe, De Zorzi, Mariangela, Fornasarig, Mara, Alessandrini, Lara, Canzonieri, Vincenzo, Lo Re, Giovanni, Puglisi, Fabio, Steffan, Agostino, Cannizzaro, Renato, De Re, Valli
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The gene, coding for the E-cadherin protein, is linked to gastric cancer (GC) susceptibility and tumor invasion. The human epidermal growth factor receptor 2 ( ) is amplified and overexpressed in a portion of GC. is an established therapeutic target in metastatic GC (mGC). Trastuzumab, in combination with various chemotherapeutic agents, is a standard treatment for these tumors leading to outcome improvement. Unfortunately, the survival benefit is limited to a fraction of patients. The aim of this study was to improve knowledge of the and the E-cadherin alterations in the context of GC to characterize subtypes of patients that could better benefit from targeted therapy. An association between the P7- haplotype, including two polymorphisms (rs16260A-rs1801552T) and a subset of -positive mGC with better prognosis was observed. Results indicated the potential evaluation of haplotypes in mGC to stratify patients that will benefit from trastuzumab-based treatments. Moreover, data may have implications to understanding the and the E-cadherin interactions in vivo and in response to treatments.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms19010047